PDCD1 and sarcoma: Additionally, we collected two external independent immunotherapy cohorts (anti-PD-1/PD-L1/CTLA-4) and a cohort of late-stage sarcoma patients who received immunotherapy at our hospital to evaluate the performance of DRGs in predicting immunotherapy response.